KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Jazz Pharmaceuticals (JAZZ) Short-term Investments (2016 - 2017)

Jazz Pharmaceuticals has reported Short-term Investments over the past 4 years, most recently at $200.0 million for Q3 2017.

Quarterly results put Short-term Investments at $200.0 million for Q3 2017, up 236.6% from a year ago — trailing twelve months through Sep 2017 was $200.0 million (up 236.6% YoY), and the annual figure for FY2016 was $60.0 million, changed.
Short-term Investments for Q3 2017 was $200.0 million at Jazz Pharmaceuticals, up from $80.0 million in the prior quarter.
Over the last five years, Short-term Investments for JAZZ hit a ceiling of $200.0 million in Q3 2017 and a floor of $764000.0 in Q1 2016.